HALOZYME THERAPEUTICS INC (HALO:NASDAQ)
$67.82 0.74 (1.1032%)
Analysed HALOZYME THERAPEUTICS INC (HALO:NASDAQ) News Sources
3 Cash-Producing Stocks with Exciting Potential
10-04-2026
yahoo.com
Did Halozyme’s Vertex Hypercon Licensing Deal Just Shift Halozyme Therapeutics’ (HALO) Investment Narrative?
10-04-2026
yahoo.com
2 Small-Cap Stocks with Solid Fundamentals and 1 We Ignore
09-04-2026
yahoo.com
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
09-04-2026
yahoo.com
Halozyme and Vertex sign deal for Hypercon technology
08-04-2026
pharmaceutical-technology.com
1 Small-Cap Stock for Long-Term Investors and 2 We Brush Off
08-04-2026
yahoo.com
Halozyme Announces Global Collaboration and License Agreement with Vertex Pharmaceuticals for Hypercon™ Technology
07-04-2026
yahoo.com
How The Investment Story Is Shifting For Halozyme Therapeutics (HALO) After Recent Analyst Calls
04-04-2026
yahoo.com
Halozyme Therapeutics (HALO) Appoints Interim CFO Amid Growth Plans
29-03-2026
yahoo.com
Unpacking Q4 Earnings: Halozyme Therapeutics (NASDAQ:HALO) In The Context Of Other Therapeutics Stocks
25-03-2026
yahoo.com
What is the current price of HALOZYME THERAPEUTICS INC (HALO:NASDAQ)?
The current price of HALOZYME THERAPEUTICS INC (HALO:NASDAQ) is $67.82.
HALOZYME THERAPEUTICS INC (HALO:NASDAQ) absolute price change since previous trading day?
The absolute price change of HALOZYME THERAPEUTICS INC (HALO:NASDAQ) since the previous trading day is $0.74.
HALOZYME THERAPEUTICS INC (HALO:NASDAQ) percentage price change since previous trading day?
The percentage price change of HALOZYME THERAPEUTICS INC (HALO:NASDAQ) since the previous trading day is 1.1032%.
What is the most recent average sentiment score for HALOZYME THERAPEUTICS INC (HALO:NASDAQ)?
The most recent average sentiment score for HALOZYME THERAPEUTICS INC (HALO:NASDAQ) is 91 out of 100.
What is the most recent average sentiment for HALOZYME THERAPEUTICS INC (HALO:NASDAQ)?
The most recent sentiment for HALOZYME THERAPEUTICS INC (HALO:NASDAQ) is .
SEC-8K** Filing Available For HALOZYME THERAPEUTICS INC (HALO:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.